Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923506 | 0.86 | MAPT (0.54) | MAPTKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL924741 | 0.86 | MAPT (0.48) | MAPTKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL24130010 | 0.83 | CTSV (0.54) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL24130037 | 0.82 | MEN1 (0.48) | MAPTKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL24129795 | 0.82 | MAPT (0.41) | MAPTKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL24130028 | 0.80 | ALDH1A1 (0.48) | MAPTKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL24129957 | 0.79 | KIT (0.45) | MAPTKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL24130177 | 0.79 | MRGPRX1 (0.56) | MAPTKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL24130099 | 0.79 | HDAC1 (0.46) | MAPTKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL24129819 | 0.79 | ALDH1A1 (0.40) | MAPTKMT2ATDP1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7105503-B2 | Pyrazole compounds | QLT INC. (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
| EP-1276723-A2 | PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY | Kinetek Pharmaceuticals, Inc. (CA) | 2003-01-22 | — | — | EP | disclosed |
| US-6436915-B1 | ANTIPROLIFERATIVE AND ANTITUMOR AGENTS AND ANGIOGENESIS INHIBITORS | KINETEK PHARMACEUTICALS, INC. (CA) | 2002-08-20 | — | — | US | disclosed |
| US-20020042501-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001077080-A2 | PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY | KINETEK PHARMACEUTICALS, INC. (CA) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | MAPT 4573/4885KMT2A 2931/4885TDP1 646/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | MAPT 4573/4885KMT2A 2931/4885TDP1 646/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | MAPT 4000/4885KMT2A 4148/4885TDP1 286/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | MAPT 4486/4885KMT2A 3543/4885TDP1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.